Eli Lilly and Company(LLY)Company Profile & BusinessNYSE
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Eli Lilly and Company (LLY) between Apr 21, 2025 and Sep 21, 2026 consists of 182 total transactions. Among these, company executives and board members conducted 176 buys (totaling 4,385,824 shares) and 6 sells (totaling 31,828 shares). This activity resulted in a net change of 4,353,996 shares, reflecting net buying interest with an estimated net acquisitions value of $769.94M.
182 insider transactions found. Showing 10 of 182 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| SULZBERGER GABRIELLE | Director | 4 | $4958.00 | Sep 21, 2026 |
| LUCIANO JUAN R | Director | 13 | $15917.00 | Sep 21, 2026 |
| ALVAREZ RALPH | Director | 10 | $12417.00 | Sep 21, 2026 |
| FYRWALD J. ERIK | Director | 8 | $9917.00 | Sep 21, 2026 |
| SEYMOUR MELISSA | Officer | 29 | N/A | Sep 9, 2026 |
| HERNANDEZ EDGARDO | Officer | 13 | N/A | Sep 2, 2026 |
| DOZIER ERIC | Officer | 216 | N/A | Sep 2, 2026 |
| SULZBERGER GABRIELLE | Director | 4 | $4958.00 | Aug 17, 2026 |
| JONSSON PATRIK | Officer | 6,500 | $7.64 | Aug 17, 2026 |
| ALVAREZ RALPH | Director | 10 | $12417.00 | Aug 17, 2026 |
Explore More Analysis for LLY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.